The objective of the review is to evaluate whether switching IBD patients from the originator to the biosimilar IFX is safe and effective in patients with quiescent IBD receiving maintenance therapy.
This is a protocol.
The objective of the review is to evaluate whether switching IBD patients from the originator to the biosimilar IFX is safe and effective in patients with quiescent IBD receiving maintenance therapy.
This is a protocol.